OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to Piperaquine phosphate (CAS RN 85547-56-4), Piperaquine tetraphosphate (CAS RN 911061-10-4), and Piperaquine tetraphosphate hydrate (CAS RN 915967-82-7). Piperaquine is a 4-piperazinoquinoline derivative antimalarial agent. Its use declined as the first resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with artemisinin derivative dihydroartemisinin as part of the combination product Eurartesim , which was first authorized for market by the European Medicines Agency (EMA) in 2011. The rationale for such artemisinin combination therapies was to provide an inexpensive, short-course treatment regimen with a high cure rate and good tolerability that would reduce transmission and protect against the development of parasite resistance, an approach that has now been endorsed by the World Health Organization (WHO).

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Piperaquine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.